I-Aml4-Alk Fusion Speetion

Le khiti isetyenziselwa ukubona ngokukodwa iinguqu ezi-12 ze-EML4-AlK Fusion kwiisampulu zezigulana zomhlaza ezincinci ezingenasincinci kwi-vitro. Iziphumo zovavanyo zezokubhekiswa kweklinikhi kuphela kwaye akufuneki zisetyenziswe njengesiseko sonyango lomntu ngamnye. Iiklinikhi kufuneka zenze izigqibo eziqinisekileyo kwiziphumo zovavanyo ezijolise kwizinto ezinje ngemicimbi yesigulana, iimpawu zeziyobisi, impendulo yonyango, kunye nezinye izikhombisi zovavanyo lweelebhu. Umhlaza wemiphunga yeyona thum ixhaphakileyo yehlabathi, kwaye i-80% ~ 85% yamatyala ayisosimahla yomhlaza we-langs omncinci (i-NSCLC). I-Gee Fusion yeProtein enxulumene ne-echinoderm-njenge-4 (i-Eml4) kunye ne-Anaplasticy Lymphoma kinase (i-Alk) yi-NSCLC, i-Alk ikwi-chromosome 2 kwaye zahlulwe malunga ne-12,7 Izigidi zezibini izibini. Ubuncinci i-20 ye-fusion ezahlukeneyo ifunyenwe, phakathi kwe-12 i-fusions kwiTheyibhile 1 ixhaphakile, iguqukele kwi-Tod 1 (E20), i-A2B (i-A20), i-A20), i-A20), i-A20 ye-Akhawunti Iipesenti ezingama-33 kunye ne-29% yezigulana ezine-EML4-AlK fusion gene NSCLC, ngokulandelelana. I-Alk ethintela imelwe ngeCriizotinib i-molekyuli incinci ekujoliswe kuyo yaphuculwa ngenxa yotshintsho lwe-alk gene gene. Ngokuthintela umsebenzi we-Alk Tyrosine Comval, ivimba i-Dowypream ye-Downales engaqhelekanga, malunga nokuthintela ukukhula kweeseli ze-tumor, ukufezekisa unyango olujolisiweyo kumathungo. Izifundo zeklinikhi zibonakalise ukuba i-crizotinib inesitereyitha esisebenzayo esingaphezulu kwe-61% kwizigulana ezine-EML4-I-ALK SUSIONS, ngelixa iphantse yabakho kwizigulana zohlobo lwasendle. Ke ngoko, ukufunyanwa kwe-Eml4-Alk Fusion Supotion yindawo kunye nesiseko sokukhokela ukusetyenziswa kweziyobisi zeCrizinib.